January 28, 2021 -- Provention Bio has released results from a preclinical proof-of-concept study for its bispecific antibody-based molecule, PRV-3279, conducted in mouse models for Pompe disease.
PRV-3279 is a dual-affinity retargeting (DART) molecule, targeting the B-cell surface proteins CD32B and CD79B. Simultaneous engagement of these receptors, triggers inhibition of B-cell function and suppression of autoantibody production, thereby regulating B cells without causing depletion
In the study, transgenic mice received gene therapy with an adeno-associated virus 9 (AAV9) vector encoding for the enzyme acid-alpha-glucosidase (GAA) gene. Errors in the GAA gene cause Pompe disease. PRV-3279 reduced anti-AAV9 vector antibody levels in a dose-dependent manner. Coadministration of PRV-3279 with gene therapy has the potential to improve the safety and efficacy of gene therapy treatments, according to the firm.
"We believe PRV-3279 has the potential to intercept and prevent the immunogenicity of life-saving gene therapy products and other biotherapeutics," stated Ashleigh Palmer, CEO and co-founder, Provention Bio.